US8309095B2ExpiredUtilityPatentIndex 47

Parathyroid hormone receptor activation and stem and progenitor cell expansion

Assignee: SCADDEN DAVID TPriority: Jul 25, 2002Filed: Apr 29, 2011Granted: Nov 13, 2012

Est. expiryJul 25, 2022(expired)· nominal 20-yr term from priority

Inventors:SCADDEN DAVID T CALVI LAURA M ADAMS GREGOR KRONENBERG HENRY M

C12N 2502/1311A01K 2227/105C12N 5/0667C12N 5/0623G01N 33/74A61P 35/02A61K 38/29A61P 7/00C12N 5/0662A01K 2217/05C12N 2502/1394C12N 5/0647C12N 5/0668A61K 38/17C12N 5/0666C12N 5/0665C12N 2501/37C12Q 1/6809A61P 7/06A61K 35/28C07K 14/72C12N 5/0664C12N 5/0663C12N 5/0602

PatentIndex Score

Cited by

References

Claims

Abstract

The invention relates to methods for manipulating hematopoietic stem or progenitor cells, mesenchymal stem cells, epithelial stem cells, neural stem cells and related products through activation of the PTH/PTHrP receptor in neighboring cells.

Claims

exact text as granted — not AI-modified

1. A method for treating a subject having or at risk of having leukemia, the method comprising:
 administering to the subject a PTH, a PTH analogue, or a PTH/PTHrP receptor agonist in an amount effective to increase the amount of normal hematopoietic stem and progenitor cells; and 
 decreasing the amount of leukemic or pre-leukemic cells, thereby treating a subject having or at risk of having leukemia. 
 
     
     
       2. The method of  claim 1 , wherein the leukemia is chronic. 
     
     
       3. The method of  claim 2 , wherein the chronic leukemia is chronic myeloid, chronic myelogenous or chronic granulocytic leukemia. 
     
     
       4. The method of  claim 1 , wherein the leukemia is acute. 
     
     
       5. The method of  claim 4 , wherein the acute leukemia is acute lymphoblastic leukemia or acute nonlymphoblastic leukemia.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.